APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs Based on TGF-β1

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs Based on TGF-β1 Market Analysis and Forecast 2026-2032

2 January 2026194 pages

Choose your research edition.

Industry ResearchDrugs Based on TGF-β1 Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs Based on TGF-β1 Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Drugs Based on TGF-β1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs Based on TGF-β1 Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs Based on TGF-β1 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Drugs Based on TGF-β1 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drugs Based on TGF-β1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs Based on TGF-β1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs Based on TGF-β1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs Based on TGF-β1 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drugs Based on TGF-β1 include Roche and Shionogi Ltd etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs Based on TGF-β1, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs Based on TGF-β1, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs Based on TGF-β1, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs Based on TGF-β1 revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs Based on TGF-β1 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs Based on TGF-β1 revenue, projected growth trends, production technology, application and end-user industry.

Drugs Based on TGF-β1 Segment by Company

Roche

Shionogi Ltd

Drugs Based on TGF-β1 Segment by Type

Pirfenidone

Galunisertib

Others

Drugs Based on TGF-β1 Segment by Application

IPF

Cancer

Others

Drugs Based on TGF-β1 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on TGF-β1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on TGF-β1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on TGF-β1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs Based on TGF-β1 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs Based on TGF-β1 company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs Based on TGF-β1 revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs Based on TGF-β1 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pirfenidone Major Player Table 3. Galunisertib Major Player Table 4. Others Major Player Table 5. Global Drugs Based on TGF-β1 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. IPF Major Player Table 7. Cancer Major Player Table 8. Others Major Player Table 9. Drugs Based on TGF-β1 Industry Trends Table 10. Drugs Based on TGF-β1 Industry Drivers Table 11. Drugs Based on TGF-β1 Industry Opportunities and Challenges Table 12. Drugs Based on TGF-β1 Industry Restraints Table 13. Global Drugs Based on TGF-β1 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drugs Based on TGF-β1 Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drugs Based on TGF-β1 Market Share by Region (2021-2026) Table 16. Global Drugs Based on TGF-β1 Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drugs Based on TGF-β1 Market Share by Region (2027-2032) Table 18. Global Drugs Based on TGF-β1 Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drugs Based on TGF-β1 Revenue Market Share by Players (2021-2026) Table 20. Global Drugs Based on TGF-β1 Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drugs Based on TGF-β1 Key Players Headquarters & Area Served Table 22. Global Drugs Based on TGF-β1 Players, Product Type & Application Table 23. Global Drugs Based on TGF-β1 Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drugs Based on TGF-β1 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drugs Based on TGF-β1 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drugs Based on TGF-β1 Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drugs Based on TGF-β1 Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drugs Based on TGF-β1 Revenue Market Share by Type (2021-2026) Table 30. Global Drugs Based on TGF-β1 Revenue Market Share by Type (2027-2032) Table 31. Global Drugs Based on TGF-β1 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drugs Based on TGF-β1 Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drugs Based on TGF-β1 Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drugs Based on TGF-β1 Revenue Market Share by Application (2021-2026) Table 35. Global Drugs Based on TGF-β1 Revenue Market Share by Application (2027-2032) Table 36. Roche Company Information Table 37. Roche Business Overview Table 38. Roche Drugs Based on TGF-β1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Roche Drugs Based on TGF-β1 Product Portfolio Table 40. Roche Recent Development Table 41. Shionogi Ltd Company Information Table 42. Shionogi Ltd Business Overview Table 43. Shionogi Ltd Drugs Based on TGF-β1 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Shionogi Ltd Drugs Based on TGF-β1 Product Portfolio Table 45. Shionogi Ltd Recent Development Table 46. North America Drugs Based on TGF-β1 Revenue by Type (2021-2026) & (US$ Million) Table 47. North America Drugs Based on TGF-β1 Revenue by Type (2027-2032) & (US$ Million) Table 48. North America Drugs Based on TGF-β1 Revenue by Application (2021-2026) & (US$ Million) Table 49. North America Drugs Based on TGF-β1 Revenue by Application (2027-2032) & (US$ Million) Table 50. North America Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 51. North America Drugs Based on TGF-β1 Revenue by Country (2021-2026) & (US$ Million) Table 52. North America Drugs Based on TGF-β1 Revenue by Country (US$ Million) & (2027-2032) Table 53. Europe Drugs Based on TGF-β1 Revenue by Type (2021-2026) & (US$ Million) Table 54. Europe Drugs Based on TGF-β1 Revenue by Type (2027-2032) & (US$ Million) Table 55. Europe Drugs Based on TGF-β1 Revenue by Application (2021-2026) & (US$ Million) Table 56. Europe Drugs Based on TGF-β1 Revenue by Application (2027-2032) & (US$ Million) Table 57. Europe Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 58. Europe Drugs Based on TGF-β1 Revenue by Country (2021-2026) & (US$ Million) Table 59. Europe Drugs Based on TGF-β1 Revenue by Country (US$ Million) & (2027-2032) Table 60. China Drugs Based on TGF-β1 Revenue by Type (2021-2026) & (US$ Million) Table 61. China Drugs Based on TGF-β1 Revenue by Type (2027-2032) & (US$ Million) Table 62. China Drugs Based on TGF-β1 Revenue by Application (2021-2026) & (US$ Million) Table 63. China Drugs Based on TGF-β1 Revenue by Application (2027-2032) & (US$ Million) Table 64. Asia Drugs Based on TGF-β1 Revenue by Type (2021-2026) & (US$ Million) Table 65. Asia Drugs Based on TGF-β1 Revenue by Type (2027-2032) & (US$ Million) Table 66. Asia Drugs Based on TGF-β1 Revenue by Application (2021-2026) & (US$ Million) Table 67. Asia Drugs Based on TGF-β1 Revenue by Application (2027-2032) & (US$ Million) Table 68. Asia Drugs Based on TGF-β1 Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 69. Asia Drugs Based on TGF-β1 Revenue by Region (US$ Million) & (2021-2026) Table 70. Asia Drugs Based on TGF-β1 Revenue by Region (US$ Million) & (2027-2032) Table 71. SAMEA Drugs Based on TGF-β1 Revenue by Type (2021-2026) & (US$ Million) Table 72. SAMEA Drugs Based on TGF-β1 Revenue by Type (2027-2032) & (US$ Million) Table 73. SAMEA Drugs Based on TGF-β1 Revenue by Application (2021-2026) & (US$ Million) Table 74. SAMEA Drugs Based on TGF-β1 Revenue by Application (2027-2032) & (US$ Million) Table 75. SAMEA Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. SAMEA Drugs Based on TGF-β1 Revenue by Country (2021-2026) & (US$ Million) Table 77. SAMEA Drugs Based on TGF-β1 Revenue by Country (US$ Million) & (2027-2032) Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Drugs Based on TGF-β1 Image Figure 2. Global Drugs Based on TGF-β1 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs Based on TGF-β1 Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pirfenidone Image Figure 5. Galunisertib Image Figure 6. Others Image Figure 7. Global Drugs Based on TGF-β1 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs Based on TGF-β1 Market Size Share 2021 VS 2025 VS 2032 Figure 9. IPF Image Figure 10. Cancer Image Figure 11. Others Image Figure 12. Global Drugs Based on TGF-β1 Market Size (US$ Million) & (2021-2032) Figure 13. Global Drugs Based on TGF-β1 Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drugs Based on TGF-β1 Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drugs Based on TGF-β1 Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drugs Based on TGF-β1 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drugs Based on TGF-β1 Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drugs Based on TGF-β1 Revenue Market Share by Type (2021-2032) Figure 20. Global Drugs Based on TGF-β1 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drugs Based on TGF-β1 Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drugs Based on TGF-β1 Revenue Market Share by Application (2021-2032) Figure 23. North America Drugs Based on TGF-β1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drugs Based on TGF-β1 Revenue Share by Type (2021-2032) Figure 25. North America Drugs Based on TGF-β1 Revenue Share by Application (2021-2032) Figure 26. North America Drugs Based on TGF-β1 Revenue Share by Country (2021-2032) Figure 27. United States Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drugs Based on TGF-β1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drugs Based on TGF-β1 Revenue Share by Type (2021-2032) Figure 32. Europe Drugs Based on TGF-β1 Revenue Share by Application (2021-2032) Figure 33. Europe Drugs Based on TGF-β1 Revenue Share by Country (2021-2032) Figure 34. Germany Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drugs Based on TGF-β1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drugs Based on TGF-β1 Revenue Share by Type (2021-2032) Figure 44. China Drugs Based on TGF-β1 Revenue Share by Application (2021-2032) Figure 45. Asia Drugs Based on TGF-β1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drugs Based on TGF-β1 Revenue Share by Type (2021-2032) Figure 47. Asia Drugs Based on TGF-β1 Revenue Share by Application (2021-2032) Figure 48. Asia Drugs Based on TGF-β1 Revenue Share by Region (2021-2032) Figure 49. Japan Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drugs Based on TGF-β1 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drugs Based on TGF-β1 Revenue Share by Type (2021-2032) Figure 57. SAMEA Drugs Based on TGF-β1 Revenue Share by Application (2021-2032) Figure 58. SAMEA Drugs Based on TGF-β1 Revenue Share by Country (2021-2032) Figure 59. Brazil Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drugs Based on TGF-β1 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Galunisertib
  • Others
Applications
  • IPF
  • Cancer
  • Others
Companies covered
  • Roche
  • Shionogi Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs Based on TGF-β1 Market by Type
  3. 1.2.1 Global Drugs Based on TGF-β1 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pirfenidone
  5. 1.2.3 Galunisertib
  6. 1.2.4 Others
  7. 1.3 Drugs Based on TGF-β1 Market by Application
  8. 1.3.1 Global Drugs Based on TGF-β1 Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 IPF
  10. 1.3.3 Cancer
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drugs Based on TGF-β1 Market Dynamics
  1. 2.1 Drugs Based on TGF-β1 Industry Trends
  2. 2.2 Drugs Based on TGF-β1 Industry Drivers
  3. 2.3 Drugs Based on TGF-β1 Industry Opportunities and Challenges
  4. 2.4 Drugs Based on TGF-β1 Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs Based on TGF-β1 Market Perspective (2021-2032)
  2. 3.2 Global Drugs Based on TGF-β1 Growth Trends by Region
  3. 3.2.1 Global Drugs Based on TGF-β1 Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs Based on TGF-β1 Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs Based on TGF-β1 Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs Based on TGF-β1 Revenue by Players
  2. 4.1.1 Global Drugs Based on TGF-β1 Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs Based on TGF-β1 Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs Based on TGF-β1 Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs Based on TGF-β1 Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs Based on TGF-β1 Key Players Headquarters & Area Served
  7. 4.4 Global Drugs Based on TGF-β1 Players, Product Type & Application
  8. 4.5 Global Drugs Based on TGF-β1 Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs Based on TGF-β1 Market CR5 and HHI
  11. 4.6.3 2025 Drugs Based on TGF-β1 Tier 1, Tier 2, and Tier 3
5 Drugs Based on TGF-β1 Market Size by Type
  1. 5.1 Global Drugs Based on TGF-β1 Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs Based on TGF-β1 Revenue by Type (2021-2032)
  3. 5.3 Global Drugs Based on TGF-β1 Revenue Market Share by Type (2021-2032)
6 Drugs Based on TGF-β1 Market Size by Application
  1. 6.1 Global Drugs Based on TGF-β1 Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs Based on TGF-β1 Revenue by Application (2021-2032)
  3. 6.3 Global Drugs Based on TGF-β1 Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Drugs Based on TGF-β1 Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche Drugs Based on TGF-β1 Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Shionogi Ltd
  8. 7.2.1 Shionogi Ltd Company Information
  9. 7.2.2 Shionogi Ltd Business Overview
  10. 7.2.3 Shionogi Ltd Drugs Based on TGF-β1 Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Shionogi Ltd Drugs Based on TGF-β1 Product Portfolio
  12. 7.2.5 Shionogi Ltd Recent Developments
8 North America
  1. 8.1 North America Drugs Based on TGF-β1 Revenue (2021-2032)
  2. 8.2 North America Drugs Based on TGF-β1 Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs Based on TGF-β1 Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs Based on TGF-β1 Revenue by Type (2027-2032)
  5. 8.3 North America Drugs Based on TGF-β1 Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs Based on TGF-β1 Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs Based on TGF-β1 Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs Based on TGF-β1 Revenue by Application (2027-2032)
  9. 8.5 North America Drugs Based on TGF-β1 Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs Based on TGF-β1 Revenue by Country
  11. 8.6.1 North America Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs Based on TGF-β1 Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs Based on TGF-β1 Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Drugs Based on TGF-β1 Revenue (2021-2032)
  2. 9.2 Europe Drugs Based on TGF-β1 Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs Based on TGF-β1 Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs Based on TGF-β1 Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs Based on TGF-β1 Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs Based on TGF-β1 Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs Based on TGF-β1 Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs Based on TGF-β1 Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs Based on TGF-β1 Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs Based on TGF-β1 Revenue by Country
  11. 9.6.1 Europe Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs Based on TGF-β1 Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs Based on TGF-β1 Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Drugs Based on TGF-β1 Revenue (2021-2032)
  2. 10.2 China Drugs Based on TGF-β1 Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs Based on TGF-β1 Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs Based on TGF-β1 Revenue by Type (2027-2032)
  5. 10.3 China Drugs Based on TGF-β1 Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs Based on TGF-β1 Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs Based on TGF-β1 Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs Based on TGF-β1 Revenue by Application (2027-2032)
  9. 10.5 China Drugs Based on TGF-β1 Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs Based on TGF-β1 Revenue (2021-2032)
  2. 11.2 Asia Drugs Based on TGF-β1 Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs Based on TGF-β1 Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs Based on TGF-β1 Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs Based on TGF-β1 Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs Based on TGF-β1 Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs Based on TGF-β1 Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs Based on TGF-β1 Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs Based on TGF-β1 Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs Based on TGF-β1 Revenue by Country
  11. 11.6.1 Asia Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs Based on TGF-β1 Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs Based on TGF-β1 Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs Based on TGF-β1 Revenue (2021-2032)
  2. 12.2 SAMEA Drugs Based on TGF-β1 Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs Based on TGF-β1 Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs Based on TGF-β1 Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs Based on TGF-β1 Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs Based on TGF-β1 Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs Based on TGF-β1 Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs Based on TGF-β1 Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs Based on TGF-β1 Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs Based on TGF-β1 Revenue by Country
  11. 12.6.1 SAMEA Drugs Based on TGF-β1 Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs Based on TGF-β1 Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs Based on TGF-β1 Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst